Plot Planting Automation Enables Seed Research Efficiencies
NEVADA, IOWA / ACCESS Newswire / March 19, 2025 / In the seed research industry, technological advancements are revolutionizing the approach to plot planting and cultivation. Seed research professionals face numerous challenges, including labor shortages, increasing efficiency requirements, the push for faster advancement decisions, and more. Each year, it becomes clearer that planting automation is essential in removing human error and closing gaps in seed research needs. Operators do not need to unload seed packets for each plot, which supports seed research professionals in many ways.PowerPlant Automated Planting System from ALMACO PowerPlant Automated Planting System on an ALMACO SeedPro 360 Research Planter
Planting automation embodies the transformative potential of new technology in seed research. At the forefront of this shift in automated planting technology is the ALMACO PowerPlant Automated Planting System. The first of its kind in the seed research industry, it has far exceeded the reliability standards of traditional plot planting methods.
Seed cartridges are packaged, labeled, and verified ahead of time, providing ultimate peace of mind. Seed researchers can go into the field knowing exactly where their seeds will be planted, with no secondary operator required to ride on the planter. The elimination of manual seed packet unloads reduces the risk of human error, resulting in more accurate data during harvest. Automation mitigates the labor-intensive nature of manual plot planting, allowing researchers to allocate their time and resources more effectively. The increased efficiency not only removes human error but also accelerates the pace of research and development.
Planting automation ensures that each seed is planted with consistent precision, reducing variability in research plots. This precise control of seed placement leads to more consistent field conditions, better data collection, and faster advancement decisions. By minimizing discrepancies, researchers can rely on the integrity of their data, which is crucial for making informed decisions about seed development and improvement.
With an expanded capacity, seed scientists can explore a wide variety of seed offerings to ensure the best seeds end up in farmers' hands. The ability to test and analyze more seeds in a shorter period significantly speeds up the innovation process, leading to the development of superior seed varieties that can meet the demands of a growing global population.
The integration of planting automation eliminates the need for operators to physically ride on the planter during plot planting operations. This enhancement in operator safety significantly reduces the risk of accidents, physical strain injuries, exposure to chemicals, heat stress, sunburn, and other potential hazards associated with manual operation. Ensuring the well-being of operators is a critical component of modernizing the seed research industry, making it a more attractive field for skilled professionals.
Embracing automation is not just a trend but a necessary step toward meeting the global challenges of food security and agricultural sustainability. The ALMACO PowerPlant Automated Planting System is at the forefront of this transformation, setting a new standard for excellence in seed research and development.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
16 hours ago
- Associated Press
Imagene AI Hits $45M in Total Funding After Completing $23M Series B Led by Larry Ellison
Imagene AI delivers a living intelligence engine for adaptive, insight-driven precision medicine. MIAMI, FL / ACCESS Newswire / July 1, 2025 / Imagene AI, a pioneer in multi‑modal foundation models for precision medicine, today announced the successful close of a $23 million Series B financing round led by Oracle Chairman and CTO Larry Ellison. This latest infusion brings Imagene AI's total capital raised to $45 million under terms that reflect the company's accelerating momentum and expanding strategic footprint. The round also included participation from existing investor Aguras Pathology Investments. 'We are honored to have the continued support of one of the world's foremost technology visionaries,' said Dean Bitan, CEO and Co‑founder of Imagene AI. 'We're developing the core intelligence that allows precision medicine to function as an adaptive, insight-driven system - from real-time trial design to rapid patient identification and more informed clinical decisions. Our goal is to make every trial more responsive, every insight more actionable, and every patient journey more personalized.' 'Imagene AI's ability to unite imaging, omics, and clinical data in a single foundation model is exactly the kind of breakthrough we believe will drive the next generation of drugs and diagnostics,' said Larry Ellison, Oracle Chairman and CTO. 'Their approach opens the door to a more adaptive, biologically fluent era of precision medicine.' Powering Living Precision Medicine Through Adaptive Intelligence At the core of Imagene AI is a dynamic intelligence infrastructure, an orchestration layer that continuously evolves with every stream of biological and clinical data. Histopathology, molecular profiles, and clinical context are routed in real-time through our proprietary foundation models, large language models, and biology-tuned analysis continuous loop ensures insights remain current and biologically grounded, empowering clinicians and researchers with personalized, up-to-date guidance at every stage of the trial. This momentum builds on a series of important milestones. Imagene AI's state-of-the-art digital pathology foundation model, trained on more than 1.5 million biopsy images, has demonstrated benchmark performance in key research tasks, particularly when working with limited data, a challenge common in real-world scenarios. The company launched the OI Suite platform to a broader community of users, including non-AI experts, delivering capabilities for biomarker discovery, indication expansion, and patient identification across multiple therapeutic areas. Additionally, Imagene AI is expanding strategic collaborations, such as its partnership with Tempus, to bring rapid predictive assays to more clinicians and patients, guiding treatment decisions with greater precision. Contact InformationAvital Rabani VP of Marketing SOURCE: Imagene press release
Indianapolis Star
a day ago
- Indianapolis Star
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors Company will also develop a subcutaneous version, PN-477sc, as a once-weekly injection IND-enabling studies underway, with Phase I study initiation expected in 2Q26 Webcast and conference call to be held today at 4:30 pm ET NEWARK, CALIFORNIA / ACCESS Newswire Protagonist Therapeutics, Inc. ('Protagonist' or the 'Company') today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, GCG receptor triple agonist peptide with oral and subcutaneous routes of administration, as a development candidate for the treatment of obesity. The triple agonist PN-477 is designed to offer the optimal combination of total body weight loss, improved gastrointestinal (GI) tolerability and fat to lean mass ratio, with the dosing convenience of a once-daily oral agent and the added optionality of a once-weekly subcutaneous administration. 'We are very pleased to nominate development candidate PN-477, a promising potential best-in class oral GLP-1, GIP, GCG receptor tri-agonist peptide which has demonstrated optimal absolute and relative activity against all three hormone receptors in preclinical testing,' said Dinesh V. Patel, PhD, President and CEO of Protagonist. 'PN-477 is specifically engineered to be orally stable with attention to the relative balance of potencies against the three receptors to potentially leverage their beneficial effects on weight loss and optimal body composition while mitigating their adverse effects. As with our previous drug candidates and late-stage assets, PN-477 is a testament to the power of our peptide technology platform, including the ability to deliver first- and best-in-class targeted oral and injectable peptide therapeutics.' PN-477 has completed extensive preclinical evaluation including oral and metabolic stability, potency, pharmacokinetics and pharmacodynamics studies, and has demonstrated effects in preclinical models of obesity and glycemic control. PN-477 has shown potent in vitro activity in activating the GLP-1, GIP, and GCG receptors. PN-477 also demonstrated robust preclinical proof-of-concept in various animal studies including the diet induced obesity (DIO) preclinical mouse model, normal dogs, and cynomolgus monkeys. Overall, PN-477 has the right balance of potency, oral and in-vivo stability, and pharmacokinetic properties to enable parallel development both as a once-daily oral (PN-477o) and once-weekly injectable (PN-477sc) treatment options. IND enabling studies of PN-477 are underway and initiation of Phase 1 clinical studies is anticipated in the second quarter of 2026. 'While GLP-1 agonists have dominated the market thus far, there remains a broad opportunity for novel therapeutics with better body weight loss, higher ratio of fat to lean mass loss, tolerability and additional beneficial effects in obesity-related comorbidities. A triple GLP-1, GIP, GCG receptor agonist peptide that offers weight loss on par with the best injectable treatments options, as well as the optionality provided by both oral and injectable routes of administration, would be an important therapeutic breakthrough and represents another potential blockbuster drug opportunity for Protagonist,' added Dr. Patel. 'We look forward to moving PN-477 into first-in human clinical Phase 1 studies in the second quarter of 2026.' Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Monday, June 30 th at 4:30 pm ET are: US-based Investors: 1-877-407-0752 International Investors: 1-201-389-0912 Conference Call ID: 13754335 The webcast link for the event can be found here: A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event. About Protagonist Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to J&J Innovative Medicines ('JNJ'), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and oral hepcidin. More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of PN-477, and the timing of PN-477 clinical development. In some cases, you can identify these statements by forward-looking words such as 'anticipate,' 'believe,' 'may,' 'will,' 'expect,' or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading 'Risk Factors' contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Investor Relations Contact Corey Davis, Ph.D. LifeSci Advisors cdavis@ +1 212 915 2577 Media Relations Contact Virginia Amann ENTENTE Network of Companies virginiaamann@ +1 833 500 0061 ext. 1 SOURCE: Protagonist Therapeutics View the original press release on ACCESS Newswire
Yahoo
2 days ago
- Yahoo
MIT spinoff aims to build first-of-its-kind US facility to deliver limitless energy — here's what you need to know
Commonwealth Fusion Systems just filed a permit to build what's being touted as the world's first grid-scale commercial fusion power plant — and the company wants to do it in Chesterfield County, Virginia. The Massachusetts-based company is planning a 400-megawatt facility called ARC to be built at the James River Industrial Park on land leased from Dominion Energy, according to the CFS website. If approved, construction would start in the late 2020s. They're aiming to be up and running in the early 2030s, with a planned operational life of 20 years or more. Fusion is what powers the sun. It works by forcing two small atoms — often the hydrogen isotopes deuterium and tritium — to merge into one and become helium. When that happens, it gives off a ton of energy, without the long-term radioactive waste that comes from nuclear fission. Scientists have been chasing this for decades. Now, it's starting to look more real. If successful, this could mark a major turning point in how we produce and consume energy. The ARC design uses magnets to hold the fusion reaction in place and molten salt to absorb heat, according to reports from the Massachusetts Institute of Technology and researchers at the Sapienza University of Rome. Heat captured in the process will turn water into steam, spin a turbine, and generate electricity, as detailed by If it works the way it's designed to, this plant could provide massive amounts of power without relying on dirty energy or producing carbon emissions. It would also create a scalable model for future fusion development in other parts of the country. Commonwealth started assembling the core tech — a tokamak, the magnetic device that makes fusion possible — back in March. That system, called SPARC, is being built in Massachusetts and is expected to go live in 2026. The company spun out of MIT in 2018. It has raised more than $2 billion since and now has over 1,000 employees, according to the CFS website. There are still approvals needed at the county, state, and federal levels — and the technology is under development — but if all goes as planned, the project could reshape what's possible for clean, stable power. Should the U.S. invest more in battery innovations? Absolutely Depends on the project We're investing enough We should invest less Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
